Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q3

8129.TEDINET S100Q4UF
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥1.06T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥950.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.4bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.9bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥14.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥10.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥9.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥9.6bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥794.4bnat 2022-12-31Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥731.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥554.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥240.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥238.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥112.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥136.092022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥97.982021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.582021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥125.12022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥90.072021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio30.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-12-31¥7.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-12-31¥715m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-12-31¥1.02T
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-12-31¥983.6bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥4.9bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥449m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.06T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥43.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥9.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.4bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-12-31¥6.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-12-31¥691m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-12-31¥913.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-12-31¥876.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥37.0bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.6bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.1bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1.0bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥308m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥993.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥950.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥43.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Short term loans payablePrior1YearInstant6545000000JPY
Short term loans payableCurrentQuarterInstant2870000000JPY
Current portion of bondsPrior1YearInstant－JPY
Current portion of bondsCurrentQuarterInstant20008000000JPY
Income taxes payablePrior1YearInstant5416000000JPY
Income taxes payableCurrentQuarterInstant1950000000JPY
Provision for bonusesPrior1YearInstant3252000000JPY
Provision for bonusesCurrentQuarterInstant1575000000JPY
Provision for directors bonusesPrior1YearInstant53000000JPY
Provision for directors bonusesCurrentQuarterInstant31000000JPY
Asset retirement obligations clPrior1YearInstant4000000JPY
Asset retirement obligations clCurrentQuarterInstant1000000JPY
Other clPrior1YearInstant17535000000JPY
Other clCurrentQuarterInstant18361000000JPY
Current liabilitiesPrior1YearInstant402819000000JPY
Current liabilitiesCurrentQuarterInstant513629000000JPY
Bonds payablePrior1YearInstant20023000000JPY
Bonds payableCurrentQuarterInstant－JPY
Long term loans payablePrior1YearInstant12596000000JPY
Long term loans payableCurrentQuarterInstant14098000000JPY
Net defined benefit liabilityPrior1YearInstant2423000000JPY
Net defined benefit liabilityCurrentQuarterInstant2479000000JPY
Asset retirement obligations nclPrior1YearInstant2741000000JPY
Asset retirement obligations nclCurrentQuarterInstant2753000000JPY
Provision for loss on anti monopoly act nclPrior1YearInstant3639000000JPY
Provision for loss on anti monopoly act nclCurrentQuarterInstant5039000000JPY
Other nclPrior1YearInstant16850000000JPY
Other nclCurrentQuarterInstant15999000000JPY
Noncurrent liabilitiesPrior1YearInstant58275000000JPY
Noncurrent liabilitiesCurrentQuarterInstant40369000000JPY
LiabilitiesPrior1YearInstant461095000000JPY
LiabilitiesCurrentQuarterInstant553998000000JPY
Capital stockPrior1YearInstant10649000000JPY
Capital stockCurrentQuarterInstant10649000000JPY
Capital surplusPrior1YearInstant49228000000JPY
Capital surplusCurrentQuarterInstant49146000000JPY
Retained earningsPrior1YearInstant180254000000JPY
Retained earningsCurrentQuarterInstant187576000000JPY
Treasury stockPrior1YearInstant-15719000000JPY
Treasury stockCurrentQuarterInstant-23107000000JPY
Shareholders equityPrior1YearInstant224413000000JPY
Shareholders equityCurrentQuarterInstant224265000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant20792000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant20158000000JPY
Revaluation reserve for landPrior1YearInstant-4273000000JPY
Revaluation reserve for landCurrentQuarterInstant-4276000000JPY
Valuation and translation adjustmentsPrior1YearInstant16518000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant15881000000JPY
Subscription rights to sharesPrior1YearInstant149000000JPY
Subscription rights to sharesCurrentQuarterInstant146000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass